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AcylcarnitinesFollowing a screening on EMS-induced Drosophila mutants defective for formation and morphogenesis of
epithelial cells, we have identiﬁed three lethal mutants defective for the production of embryonic cuticle.
The mutants are allelic to the CG12140 gene, the ﬂy homologue of electron transfer ﬂavoprotein:ubiquinone
oxidoreductase (ETF:QO). In humans, inherited defects in this inner membrane protein account for multiple
acyl-CoA dehydrogenase deﬁciency (MADD), a metabolic disease of β-oxidation, with a broad range of clinical
phenotypes, varying from embryonic lethal to mild forms. The three mutant alleles carried distinct missense
mutations in ETF:QO (G65E, A68V and S104F) and maternal mutant embryos for ETF:QO showed lethal
morphogenetic defects and a signiﬁcant induction of apoptosis following germ-band elongation. This pheno-
type is accompanied by an embryonic accumulation of short- and medium-chain acylcarnitines (C4, C8 and
C12) as well as long-chain acylcarnitines (C14 and C16:1), whose elevation is also found in severe MADD
forms in humans under intense metabolic decompensation. In agreement the ETF:QO activity in the mutant
embryos is markedly decreased in relation to wild type activity. Amino acid sequence analysis and structural
mapping into a molecular model of ETF:QO show that all mutations map at FAD interacting residues, two of
which at the nucleotide-binding Rossmann fold. This structural domain is composed by a β-strand connected
by a short loop to an α-helix, and its perturbation results in impaired cofactor association via structural
destabilisation and consequently enzymatic inactivation. This work thus pinpoints the molecular origins of
a severe MADD-like phenotype in the fruit ﬂy and establishes the proof of concept concerning the suitability
of this organism as a potential model organism for MADD.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Multiple acyl-CoA dehydrogenase deﬁciency (MADD, OMIM:
231680), also known as glutaric aciduria type II, is an inherited disorder
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l rights reserved.defects in either electron transfer ﬂavoprotein (ETF) or in electron
transfer ﬂavoprotein:ubiquinone oxidoreductase (ETF:QO). These two
proteins constitute a metabolic hub through which electrons shuttled
by at least 11 acyl-CoA dehydrogenases (ACDHs), resulting from fatty
acid oxidation, amino acid and choline catabolism [1], are transferred
to the mitochondrial respiratory chain via the quinone pool. ETF is a
dimer of 30 kDa (ETFα) and 28 kDa (ETFβ) subunits held by a structural
AMP and containing a FADwhich oxidises the different ACDHs shuttling
electrons to ETF:QO, its redox partner. ETF:QO is a 64 kDa monomer
which binds to the inner mitochondrial membrane possibly via an
amphipatic helix, and it contains different cofactors ([4Fe–4S], FAD,
ubiquinone) organised in distinct structural domains. Genetic lesions in
any of the genes encoding for these proteins, frequently pointmutations,
yield rather distinct clinical phenotypes. These range from extremely
severe forms resulting in death at the embryonic (type I) or neonatal
stage (type II), to mild forms (type III) which can be controlled through
diet and in some cases riboﬂavin [2], carnitine and CoQ10 supplementa-
tion. Nevertheless, even these ‘mild’ cases are frequently life-threatening,
1285E. Alves et al. / Biochimica et Biophysica Acta 1822 (2012) 1284–1292for example in children as a result of metabolic decompensation during
fever and sugar depletion.
The functional failure in ETF and ETF:QO variants carrying missense
mutations hasmultiple origins, fromdefects in protein biogenesis, folding
and stability, to catalytic impairment due to a perturbation of the cofac-
tors. Among these, FAD plays a pivotal role, not only in ETF [3,4] and
ETF:QO, but also in all acyl-CoA dehydrogenases which also harbour
this organic cofactor [5]. In fact, the ﬂavin moiety is determinant for
protein structure and function: catalytically, it is very versatile as its
oxidation–reduction properties can be ﬁne-tuned through interactions
with the polypeptide chain at the binding pockets [6,7], and the many
structures available also show the important structural role it plays in
the protein three-dimensional organisation [8–13]. This cross-talk is
clearly illustrated in the Rossmann fold, a nucleotide binding structural
domain also present in ETF:QO, which comprises a β-strand connected
by a short loop to an α-helix, and includes an expanded sequence motif
(V/IxGx1–2GxxGxxxG/A) that affords both FAD binding and stabilisation
of the secondary structure elements involved [14]. Small changes in the
FAD interacting residues may change the redox potential of the ﬂavin,
its afﬁnity towards the protein, or ultimately disrupt binding, with conse-
quent enzymatic inactivation and structural disruption. Moreover, the
relevance of ﬂavins as cofactors also results from the fact that they are
able to carry out both one and two electron transfer reactions [2].
In spite of a growing understanding of the biochemical details of
defective processes in β-oxidation, as well as an increasing expansion
of the genotypic and phenotypic characteristics of patients suffering
from MADD, the fact is that cellular studies have been mostly limited
to patient ﬁbroblasts. However, recent studies have opened the per-
spective of implementing organism models for MADD by addressing
the effects of defects in ETF:QO in zebraﬁsh and in the nematode
Caenorhabditis elegans [15,16]. These have been the cases of the study
on the zebraﬁshmutant xavwhich corresponds to a non-sensemutation
that results in an inactivating truncation of ETF:QO [15], and in the nem-
atode, two mutant alleles of let-721 which correspond to deleterious
point mutations in ETF:QO [16]. These studies exemplify how model
organisms can contribute to a broader biological understanding of
processes affected in MADD—for example the zebraﬁsh study elicited
that neurogenesis is affected through the PPARG–ERK pathway and
the nematode work puts in evidence that ETF:QO is expressed under
complex transcriptional control.
In this work we report the genotypic, phenotypic and biochemical
characteristics of a severe MADD-like phenotype in the fruit ﬂy
Drosophila melanogaster, establishing the proof of principle concerning
the suitability of this organism as a potential model not only for
MADD but also for inherited fatty acid disorders in general. Our focus
on this study has been to correlate developmental defects of Drosophila
mutants with speciﬁc alterations at the level of protein structure and
stability. We have established that three independent mutant alleles,
corresponding to three distinct point mutations in ETF:QO, are lethal
as a result of a speciﬁc knock-down of FAD binding by direct
disruption of the cofactor binding motif within the nucleotide binding
Rossmann fold. This study thus provides a direct molecular rationale
for the effect of speciﬁc mutations at the cellular and structural levels,
and offers a platform to test in Drosophila a range of MADD-mutations
yielding diverse clinical phenotypes, from severe to milder forms of
the disease.
2. Materials and methods
2.1. Fly work
All ETF:QO alleles were isolated from a previously reportedmaternal
screen [17]. All ﬂies were raised at 25 °C using standard techniques.
Riboﬂavin supplementation of the medium was also tested from 0.2 to
5 mM. To generate ETF:QO mutant clones (negative for nuclear GFP
label; nGFPminus), females y, w, hsFLP; FRT42B nGFP/CyO hshid werecrossed with males w; FRT42B, ETF:QO/CyO. The offspring was heat-
shocked two times for 1 h at 37 °C during second and third instar larvae.
To generate homozygous clones of ETF:QO in wing imaginal discs,
female y, w, hsFLP; FRT42B nGFP/CyO hshid ﬂies were crossed with
w; FRT42B, ETF:QO/CyO males. The offspring was heat shocked for 1 h
at 37 °C, 48 h after a 24-hour egg collection, corresponding to second
instar larvae.Wing discswere dissected from crawling third instar larvae.
Maternal mutant embryos for ETF:QO were obtained using the FLP/
FRTovoD system [18]. w; FRT42B ETF:QO/CyO virgins were crossed to y,
w, hsFLP; FRT42B ovoD/CyO hshid males at 25 °C and the progeny was
heat-shocked two times at 37 °C for 1 h during second and third instar.
2.2. Mapping and cloning of ETF:QO alleles
Complementation Group 1 mutant alleles were mapped using the
Bloomington 2Rdeﬁciency kit to chromosome region46C. By a candidate
gene approach we concluded that all three different alleles of Group 1
(A56-12, B42-1 and B43-36) were most likely mutant alleles of ETF:QO
as they failed to complement a lethal P-element (w[1118]; PBac{w
[+mC]=WH}CG12140[f05640]) associated with the ETF:QO gene locus.
Molecular characterisation of the isolated ETF:QO alleles identiﬁed differ-
ent point mutations within the coding region of this gene. All mutations
were independently sequenced three times from different PCR reactions
andwe used amutant allele isolated in the same screen but from a differ-
ent complementation group to identify single-nucleotide polymorphisms
present in the original mutagenised stock.
2.3. Immunostainings
Third instar wing imaginal disc ﬁxation and staining were per-
formed using standard procedures [19]. For maternal phenotypic
analysis, embryos were ﬁxed and stained using standard procedures
[17]. The oogenesis phenotypic analysis was performed with tissue
dissected from 2 or 3 days old females where mutant clones were in-
duced by heat-shock at second instar larvae stages, and ﬁxed in phos-
phate buffered saline (PBS) with 4% formaldehyde for 20 min.
Primary antibodies used were anti-Armadillo N2 7A1 mouse at 1:20
(Developmental Studies Hybridoma Bank (DSHB)), anti-Cleaved
Caspase-3 rabbit at 1:500 (Cell Signaling, 9661S), anti-Neurotactin
mouse clone BP106 at 1:133 (DSHB) and anti-pTyr mouse at 1:1000
(Cell Signaling, 9411). Secondary antibodies were Cy3- and Cy5-
conjugated at 1:1000 (Jackson ImmunoResearch Laboratories, West
Grove, PA). For F-Actin staining, Phaloidin-Rhodamine was used at
1:200 (Sigma) (stock concentration 1 mg.ml−1) with 5 min incuba-
tion. Ovaries and embryos were mounted in ﬂuorescent mounting
medium (DakoCytomation, Inc.) and wing discs were mounted in
Vectashield (Vector Laboratories). Samples were visualised with a
Leica SP5 confocal microscope.
2.4. Acylcarnitine analysis
For each assay, approximately 20 mg of biological samples was
used. The thawed embryos, which had been harvested 0–6 h after
egg laying and stored in 20% Glycerol at −80 °C, were centrifuged
at 12,000×g for 10 min to remove glycerol. Embryos were then
resuspended in 200 μl of sucrose buffer (200 mM sucrose, 10 mM
MOPS pH 7.2, 0.1 mM EDTA) and centrifuged again. Sucrose buffer
was removed and the embryos were washed two more times before
being homogenised with a pestle in sucrose buffer containing
0.5 mM of phenylmethylsulphonylﬂuoride (PMSF) (Roth). The solutions
were sonicated during 30 s at 10% intensity 2 times, with an interval of
1 min, before being submitted to a speed vacuum in order to decrease
the volume to approximately 50 μl. The embryoproteinswere quantiﬁed
by the Bradfordmethod, and the same amount of protein was applied in
the Whatman 903® ﬁlter paper and dried overnight away from light.
Acylcarnitine analysis by MS/MS spectrometry was carried out as
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contained a number of unknown substances that overlap with some of
the acylcarnitine standards used in the MS/MS analysis, and therefore,
unlike in blood samples for which the protocol used is optimised, it is
not possible to carry out the measurements of the routine broad range
of acylcarnitines. Thus, the results obtained refer exclusively to the me-
taboliteswhichhadno interference and could be accurately determined:
free carnitine (C0) and the carnitine derivatives of acetyl-CoA (C2),
butyryl (C4), octanoyl (C8), dodecanoyl (C12:0), tetradecanoyl (C14:0)
and hexadecenoyl (C16:1)—see Results and discussion and Supplemen-
tary Table S1.2.5. Western blot analysis
Embryos were resuspended in 200 μl of 50 mM Tris pH 7.5, with
3% SDS, 0.1 mM DTT, 1 mM EDTA, and 1 mM PMSF, and were lysed
with the help of plastic pestles against the walls of a 1.5 ml microtube.
The samples were centrifuged for 10 min at 20,000×g, and the pellet
was resuspended again with the plastic pestle. The suspension was
incubated at 37 °C for 30 min and, centrifuged at 20,000×g for
10 min. Protein concentration was determined by a modiﬁed Biuret
method [21]. Samples (50 μg of total protein) were separated using
SDS-PAGE followed by western blotting analysis. Equal gel loading
and blotting efﬁciency was assessed by the total protein staining of
the PVDF membrane with Coomassie [22]. An ETF:QO polyclonal anti-
body raised in rabbits against two synthetic human ETF:QO peptides
(p.48I_62M and p.485T_499A) was used to identify ETF:QO proteins
[23] and visualised with a peroxidase conjugated secondary antibody
reaction with Amersham ECL Prime solution (GE Healthcare).2.6. ETF:QO activity
Thawed embryos were resuspended in 50 mM Tris–HCl pH 7.5,
1 mM DTT and 0.5 mM PMSF, and were lysed with the help of a plastic
pestle against the walls of a 1.5 ml microtube. The suspension was
centrifuged at 5000×g, 10 min, and a plastic pestlewas used again to dis-
rupt unbroken cells. The sampleswere sonicated four times at 20% ampli-
tude with a 0.5 second pulse during 10 s. The membrane fraction was
obtained by ultracentrifugation at 100,000×g for 1 h. The membranes
were resuspended in 50 mM Tris–HCl pH 7.5 and dodecylmaldoside
was added to a ﬁnal concentration of 1%. After 1 h incubation at 4 °C,
the samples were centrifuged at 10,000×g, and the supernatant was
stored. The protein concentrationwas determined by themodiﬁed Biuret
method [21].
The activity of ETF:QO was measured by the disproportionation
assay as described in [24], with modiﬁcations. Experiments were per-
formed using 1 cm path length quartz ultra-micro cell (Hellma) with
5×3 mm aperture, allowing the monitoring of low volume reactions
(60 μl). The reaction mixture contained 50 mM Tris–HCl pH 7.5,
10 μM ETF, 6 units of catalase, and 1.8 unit glucose oxidase. The cuvette
was sealed with a rubber stopper and degassed by 10 repetitions of
vacuum/argon cycles. Glucose was added to a concentration of 30 mM
and the solution was incubated for 10 min under an argon purge. ETF
was reduced quantitatively to the semiquinone form with sodium
dithionite, and the formation of the characteristic semiquinone spec-
trum was followed spectrophotometrically. The reaction was initiated
by the addition of the membrane fractions from Drosophila embryos
made anaerobic by repeated vacuum/argon cycles. The disproportion-
ation of ETF was followed spectrophotometrically in dual wavelength
mode at 374 nm and 437 nm. The initial velocities were determined
from the traces resulting from the subtraction of the absorbances at
374 nm and 437 nm, and the extinction coefﬁcient of 9000 M−1 .cm−1
was used [25]. At least three replicate measurements were performed
for each variant.2.7. Sequence analysis and molecular model
The sequence of Drosophila ETF:QO was retrieved from the NCBI
databank (P55931), together with those of its human (545621) and
porcine (24652256) homologues. Multiple sequence alignment, se-
quence identity and similarity calculations, andmotif analysis were car-
ried out using Genedoc [26]. The crystallographic structure of porcine
ETF:QO (PDB: 2gmh) was used to produce a structural model of the
ﬂy ETF:QO by homology modelling (Swiss-Model). The two proteins
share a very high amino acid sequence identity (78%) thus making the
porcine enzyme an excellent structural template. The porcine ETF:QO
was used to carry out the analysis of themolecular interactions, cofactor
contacts and topological features. These analyses, togetherwith the pre-
diction of the conformation of the side chains of the mutant residues
were carried out using theWhatIFweb server and the PDBsumdatabase
[27]. Structures were inspected using PyMOL (DeLano Scientiﬁc).
2.8. Cloning, expression and puriﬁcation of Drosophila ETF
Drosophila ETFA cDNA cloned into pBlueScript SK vector was
obtained from the Berkeley Drosophila Genome Project. Drosophila
ETFB cDNA directionally cloned into the 5′EcoRI site and the 3′ Xhol
site of pOT2 vector was obtained from Berkeley Drosophila Genome
Project. The ampliﬁed sequences of ETFA and ETFB were assembled by
means of various cloning and subcloning steps and introduced between
the NcoI and AfIII sites, and NdeI and AvrII sites, respectively, of the
pETDuet-1 vector. Both target genes are preceded by a T7 promotor/
lac operator and a ribosomebinding site. Escherichia coliBL21 cells trans-
formed with the drosophila ETF plasmid were grown at 30 °C in LB
(Luria–Bertani) medium, supplemented with 100 μg.ml−1 ampicillin,
in a shaking incubator until OD532 of 0.5–0.8 was reached. Cells were
then induced with 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG)
for 4 h, and after were harvested by centrifugation.
Cells were resuspended in 10 mM Hepes pH 7.8, 10% ethylene glycol
and 0.5 mM PMSF (buffer A), in the presence of 0.1 mg.ml−1 FAD
(Sigma) andDNase (Applichem), anddisrupted in a Frenchpress. The sol-
uble extract was applied into a 20 ml Q-Sepharose fast ﬂow (Amersham
Biosciences) column equilibrated in buffer A. The column was washed
with 5 column volumes of buffer A, and bound proteins were eluted by
a linear gradient ranging from 0 to 1 M NaCl, in buffer A. ETF eluted as a
pure protein at ~200 mM salt, as shown by SDS/PAGE. Protein concentra-
tion was determined using the Bradford assay, and ﬂavin content
was determined using the molar extinction coefﬁcient ε436 nm=
13,400 M−1.cm−1 reported for FAD bound to ETF [28]. The enzymatic
activity of the puriﬁed protein was measured monitoring DCPIP reduc-
tion, in a coupled assay in which recombinant human MCAD and
octanoyl-CoAwere used, as described in [29]. One unit of catalytic activity
is deﬁned as nmol of DCPIP reduced perminute, in the conditions used in
the assay. All speciﬁc activities reported are based on total ﬂavin content.
Far-UV circular dichroism, recorded on a Jasco J-715 spectropolarimeter
with peltier temperature control, was used to analyse the protein fold
and secondary structure. Thermal unfolding with a linear temperature
increase was followed using circular dichroism (ellipticity variation at
222 nm), with a heating rate of 1 °C.min−1 and temperature increased
from 30 to 90 °C. A quartz polarised 1 mm path length cuvette (Hellma)
was used, and protein concentration was 0.1 mg.ml−1. Data were
analysed according to a two-state model, and ﬁts to the transition curves
weremade using Origin. The puriﬁed proteinwas fast-frozen using liquid
nitrogen and stored at−80 °C.
2.9. Cloning and expression of Drosophila ETF:QO
Drosophila ETF:QO synthetic gene was cloned into pGS-21a vector
between NdeI and HindIII cloning sites (GenScript, Inc). The ETF:QO
gene is preceded by a T7 promotor/lac operator, and has a 6xHis-tag
sequence in the N-terminus. ETF:QO-Ala68Val was also designed in
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different E. coli cell types (BL21, JM109, C43, and Rosetta) and differ-
ent temperatures (25 °C, 30 °C and 37 °C) were tested. Also, different
growth media were used for each cell type: LB (10 g Bacto Tryptone,
5 g Bacto Yeast extract and 10 g NaCl per litre), dYT medium (16 g
Bacto Tryptone, 10 g Bacto Yeast extract and 5 g NaCl per litre) and
rich medium for auto induction [30]. All growth media were sup-
plemented with 100 μg.ml−1 ampicillin, and protein expression was
induced with 100 μM–500 μM IPTG. Cells were harvested by centrifu-
gation, and then resuspended in 20 mM Tris pH 8.0, 1 mM DTT and
0.5 mM PMSF, in the presence of DNase, and were disrupted in a
French press. The extract was centrifuged at 10,000×g for 10 min,
and the supernatant treated by ultracentrifugation at 100,000×g for
1 h. The membrane fraction was resuspended in 20 mM Tris pH 8.0
and dodecylmadoside was added up to 1% (w/v). The presence of
ETF:QO was assayed by the quinone reduction method as described
in [25].
3. Results and discussion
3.1. ETF:QO is maternally required for Drosophila embryogenesis
Previously we isolated close to 300 independent EMS-induced
Drosophila mutant lines defective for formation and morphogenesis of
epithelial cells [17]. From the 2R (right-arm of the second chromosome)
secondary screen we isolated 47 lines out of the previously isolated 137
lines. These 47 mutant lines are defective for the production of embry-
onic cuticle (no cuticle or scraps of cuticle). Complementation studies of
these mutants allowed the identiﬁcation of nine 2R complementation
groups. All three alleles of Complementation Group 1 were maternally
lethal after induction of germ-line clones (data not shown). Similarly,
transheterozygoteswere also zygotic lethal (data not shown). Deﬁciency
mapping and candidate gene approach suggested that Group 1 mutants
were allelic to CG12140 gene (ETF:QO from here on), which encodes
the Drosophila homologue of the electron transfer ﬂavoprotein:ubiqui-
none oxidoreductase (ETF:QO), also referred in some literature as
electron transfer ﬂavoprotein dehydrogenase. The nucleotide changes
accounting for the observed phenotypes corresponded to three distinct
point mutations in the protein coding sequence: ETF:QO-p.Gly65Glu
(G65E), ETF:QO-p.Ala68Val (A68V) and ETF:QO-p.Ser104Phe (S104F).
As further discussed in a following section, the ETF:QO gene product
comprises different structural domains, and all identiﬁed lesions map
speciﬁcally within the FAD binding domain, indicating that this region
is an extremely sensitive functional hotspot. In molecular genetics
terms, although there are around 40 point mutations identiﬁed in
MADD patients that affect the ETF:QO gene, none of them corresponds
to the mutations here identiﬁed. Actually this is not surprising as the
genetic diagnosis is mostly carried out in living patients after a positive
result frommetabolic proﬁling,meaning that these patients carry genetic
lesions that correspond to milder forms of the disease (type III). The
lethal phenotype mutations that we have observed in the Drosophila
mutants would most likely result in embryonic or neonatal death,
corresponding to one of the more severe forms of the disease (type I
and II).
3.2. Maternal mutant embryos for ETF:QO display gross morphogenetic
defects and induction of apoptosis
Once fertilised, early embryonic development of the maternal
mutant embryos for ETF:QOwasnormal:without obviousmitotic defects
during syncytial blastoderm (data not shown), with normal blastoderm
cellularisation (Fig. 1E, F), and germ-band extension (Fig. 1G, H). Never-
theless, during the onset of germ-band retraction there were gross mor-
phogenetic defects and a signiﬁcant induction of apoptosis (Fig. 1I–L).
These abnormalities were indistinguishable between the three isolated
mutant alleles of ETF:QO (data not shown). These results are in apparentagreement with previous observations also reporting morphogenetic
defects in zygotic mutants of ETF (walrus), which encode for electron
transfer ﬂavoprotein (ETF) that is the redox partner of ETF:QO [31].
Although the observed phenotypes in ETF:QOmaternal mutant embryos
are signiﬁcantly more pleiotropic than the ones reported for zygotic
mutants of ETF, this is most likely due to the strong maternal contribu-
tion of ETF (modENCODE Temporal Expression Proﬁle) in these embryos
(Fig. S1).
3.3. Clonal analysis of ETF:QOmutant alleles failed to identify developmental
defects
Mutant clonal analysis of the isolated ETF:QOmutant alleles failed to
identify somatic and germ-line defects during Drosophila development.
Large somatic follicular clonesmutant for ETF:QO correctly encapsulated
the developing egg-chambers during stage 3 of the germarium (Fig. 1A,
B), and the mutant follicular cells maintained a normal epithelial archi-
tecture during oogenesis (Fig. 1B, C). Likewise, egg-chamber develop-
ment was normal when the germ-line was mutant for ETF:QO, with
normal number of nurse cells (data not shown) and, normal determina-
tion, positioning and growth of the oocyte (Fig. 1B, D). Large mutant
clones for ETF:QO were also normal in the highly proliferative larval
wing disc epithelial cells (Fig. 1M–P), with normal tissue proliferation
(Fig. 1M, N; the mutant clone that is negative for GFP has a similar size
to the control two copies GFP twin-spot clone) and normal epithelial
architecture (Fig. 1O, P; the junctional protein Armadillo is correctly
localised in the epithelial cells adherents junctions).
It is surprising that clonalmutant analysis of ETF:QOduringoogenesis
and larval development failed to retrieve obvious developmental de-
fects. We propose two alternative non-exclusive hypotheses to explain
the absence of phenotypes: 1) Drosophila cells only require relatively
low levels of ETF:QO expression/activity. Consistently, and since the
ETF:QO mutant alleles probably contain a residual enzymatic activity,
they only become rate limiting during mid-embryogenesis when
expression of this gene is extremely low (modENCODE Temporal
Expression Proﬁle) (Fig. S1); 2) Wild-type cells are able to complement
ETF:QOmetabolic functions of nearbymutant cells, even in largemutant
clones. Consistently, we only observe phenotypes in experimental con-
ditions where the entire organism is mutant for ETF:QO.
Altogether, this suggests that Drosophila embryonic development
is particularly sensitive to defects in the ETF/ETF:QO hub. In humans,
severe genetic defects resulting in loss of the ETF:QO gene product
account for one of the two most severe forms of MADD: either a
neonatal-onset form with (type I) or without (type II) congenital
and foetal anomalies. These are characterised by prominent congenital
malformations that range from kidney malformations; facial dys-
morphism with a high forehead, macrocephaly, low-set ears, hyper-
telorism and hypoplastic midface; muscular defects of the anterior
abdominal wall; and brain anomalies like cerebral pachygyria and sym-
metric warty dysplasia of the cerebral cortex [32–35]. Riboﬂavin exerts
a beneﬁcial effect in some of themilder forms ofMADD (type III) butwe
have not observed any rescue effect upon supplementation of the ﬂy
culture mediumwith this vitamin. Overall, the observed grossmorpho-
genetic defects and apoptosis in the three independent ETF:QO alleles
are highly suggestive of a complete dysfunction of the ETF:QO protein
that leads to abnormal mitochondrial fatty acid oxidation.
3.4. Acylcarnitine levels in ETF:QO mutant embryos display a proﬁle
typical of MADD
The diagnosis of fatty acid β-oxidation disorders is made by
analysing the levels of plasma acylcarnitines, which accumulate as a
result of an enzymatic deﬁciency that blocks the metabolic pathway
and causes the upstreambuild-up of fatty acyl-CoAs. In order to evaluate
the level of dysfunction of mitochondrial fatty acid β-oxidation in our
Drosophila mutant alleles, corresponding to the ETF:QO-G65E, ETF:QO-
Fig. 1. ETF:QO maternal mutant embryos showed gross morphogenetic defects and induction of apoptosis during mid-embryogenesis. Mutant clones for ETF:QO (marked by the
absence of nuclear GFP) (green (A–D)) showed no obvious defects during oogenesis, with a normal development of the somatic follicular epithelium (A–C) and of the germ-line
(B, D). Maternal mutant embryos for ETF:QO showed a normal blastoderm cellularisation (E, F) and germ-band extension (G, H), yet subsequently, there were gross morphogenetic
defects and a signiﬁcant induction of apoptosis (I–L). Mutant clones of ETF:QO in wing imaginal discs did not affect cell proliferation (mutant clonesmarked by the absence of GFP had
similar size to the control twin-spot clonemarked by two copies GFP (M, detail in N) and epithelial architecture (O–P)).Wild type (E, G and I) andmaternal mutant ETF:QO (F, H, J–L).
Embryos were stained for DNA (red (E–H) and green (I–L)), activated cleaved caspase 3 (marker for apoptosis) (red (I–K)), pTyr (green (E–H)) and Neurotactin (Nrt; membrane
marker) (red (L)). Ovaries were stained for DNA (red (A–C)) and Actin (red (D)). Wing imaginal discs were stained for Arm (red (O) and white (P)). The ETF:QO alleles used
were A68V (A–C, F, M–P), G65E (D,H), and S104F (J–L). The scale bar equals 10 μm (N–O), 20 μm (A), 40 μm (B–C), 50 μm (D and M) and 60 μm (E–F).
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carnitine and acylcarnitine derivatives by tandem mass spectrometry
(MS/MS) in embryos collected 0–6 h after egg laying (Fig. 2 and Table
S1). The measurements were carried out on total extracts of mutant
embryos using wild type embryos as reference. The results obtained
clearly show that fatty acid β-oxidation (FAO) is impaired: the total
amount of free carnitine (C0), which is used to shuttle fatty acids inside
the mitochondria, and acetyl-CoA (C2), which is the end product of the
β-oxidation pathway, are signiﬁcantly diminished in the ETF:QOmutant
alleles. The level of free carnitine in the mutant embryos (13–29 μM) is
always lower than that of the wild type (39 μM), as well as the levels of
produced acyl-CoA, which are rather decreased in the mutants
(31–45 μM) in comparison to the levels in normal embryos (98 μM)(Table S1). Interestingly, the elevated levels of acylcarnitines in the
mutant embryos are typical of MADD proﬁles: not only the short- and
medium-chain acylcarnitines (C4, C8 and C12) are raised, but also the
long-chain acylcarnitines (C14 and C16:1) whose elevation is restricted
to severe MADD forms, or under metabolic decompensation (Fig. 2).
However, the converse is not always true as MADD must involve func-
tional deﬁciency within the ETF/ETF:QO hub.
3.5. Impaired ETF:QO activity in mutant embryos
To further characterise the effect of the mutations in ETF:QO we
analysed protein levels inwhole embryo extracts.Western blot analysis
showed that polyclonal antibodies raised against human ETF:QO (see
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Fig. 2. ETF:QO maternal mutant embryos have raised acylcarnitine levels. The
acylcarnitine levels were determined in maternal mutant embryos for the three isolated
alleles (ETF:QO-G65E, ETF:QO-A68Vand ETF:QO-S104F). The acylcarnitine concentrations
representedwere determined byMS/MS (n=6). The following carnitine derivatives have
been measured: butyryl (C4), octanoyl (C8), dodecanoyl (C12:0), tetradecanoyl (C14:0)
and hexadecenoyl (C16:1). See Table S1 for concentrations and Materials and methods
for details.
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judged by the presence of a band with molecular mass matching the
theoretical value of themature protein (Fig. 3A). For themutant embryos
there is a clear decrease in ETF:QO protein levels which accounts for the
observed MADD-like phenotype (Fig. 3A). A second band was also
immune-detected at a lower molecular mass, most likely representing
a degradation product of ETF:QO (Fig. 3A). Interestingly, this additional
band is more intense in the mutants, suggesting that the mutatedA
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Fig. 3. ETF:QO protein levels are decreased in the maternal mutant embryos. Panel A:
Whole cell lysates from Drosophila embryos were extracted in 3% SDS, separated using
SDS/PAGE, and immunoblotted using a polyclonal antibody raised against human ETF:
QO (see Materials and methods). Equal gel loading and blotting efﬁciency was assessed
by the total protein staining of the PVDF membrane with Coomassie [22]. The western
blot was repeated three times and a representative experiment is shown. Panel B: ETF:
QO activity in isolated membranes from Drosophila embryos of different variants mea-
sured by the disproportionation assay. Solutions containing 10 μMETF, 6 units of catalase,
and 1.8 unit glucose oxidase were made anaerobic prior to the reduction of ETF to the
semiquinone form using sodium dithionite. The reaction was initiated by the addition
of anaerobic membrane fraction from embryos and the activity was calculated from the
initial rates of disproportionation which was followed spectrophotometrically in dual
wavelength mode at 374 nm and 437 nm (see Materials and methods). The bars show
the average of at least three determinations and the error bars represent S.E.M.proteins are more susceptible to degradation. In parallel to the decrease
in protein levels, we found that the enzymatic activity measured in iso-
lated membrane fraction of the embryos is also impaired in the mutants
(Fig. 3B).
These data indicate that ETF:QO is not completely absent from the
mutant Drosophila embryos, as a residual level of active protein is
present. This does not exclude the possibility that mutations lead to
the production of destabilised non-functional forms of the protein,
as it is possible that the weak expression of ETF:QO is a result of a
zygotic expression of wild-type protein (from a paternal wild-type
chromosome) in the maternal mutant ETF:QO embryos.
In any case, the fact that the proﬁles of the three mutant alleles are
similar to each other is in good agreement with the indistinguishable
morphogenic phenotypes. Altogether, these results show that the three
independent mutations in the ETF:QO mutant alleles dramatically
decrease the levels of functional enzyme resulting in the accumulation
of acylcarnitines as a consequence of a FAO blockage, thus severely
affecting the energy and lipid metabolisms which lead to lethal mor-
phogenic defects and embryo death.
In an attempt to characterise further this systemwe have carried out
cloning and heterologous expression of DrosophilaMADD proteins, ETF
and ETF:QO. Drosophila ETF was successfully cloned, expressed and
puriﬁed to homogeneity; the biochemical and structural characterisation
of this protein showed that its properties are identical to those of its
human homologue (Supplementary Fig. S2). However, despite all efforts
(see Materials and methods) Drosophila ETF:QO was systematically
expressed in the form of inactive inclusion bodies and no activity could
be detected in membranes puriﬁed from E. coli cells overexpressing
ETF:QO. In fact, the extreme difﬁculty of producing this protein has
also been reported for human ETF:QO [36], and this likely results from
the inability to correctly membrane-insert and assemble its multiple
cofactors during overexpression. This negative result has prevented us
to proceed with further biochemical studies on puriﬁed Drosophila
MADD proteins.3.6. Lethal mutations map at the FAD motif impairing cofactor binding
The fact that the three mutant ETF:QO alleles result in phenotypic
and metabolic proﬁles identical to those found in severe MADD is
strongly suggestive that the mutations are located in a functionally
sensitive hotspot of the protein. In order to analyse the structural
effects of the mutations on the protein, we have carried out a pair-wise
comparisonof the amino acid sequence of theDrosophila ETF:QO together
with homologous sequences from man and pig (Fig. 4A and Fig. S3).
Drosophila ETF:QO shares a high level of identity with these proteins
(64% identity and 78% similarity), in particular in what concerns critical
residues involved in: binding of the ﬂavin (FAD) and [4Fe–4S] iron
sulphur cluster (FeS) cofactors, interactions with ubiquinone (UQ), the
catalytic pocket and putative membrane anchoring segments. The
cofactors in the ETF:QO monomer are important structural elements, as
they are essential to maintain the three dimensional organisation of the
protein (Fig. 4B): perturbation of the FAD or FeS moieties results in
protein disorganisation or ultimately in its unfolding or misassembly. A
more detailed analysis of the identiﬁed mutations in the Drosophila
mutant alleles shows that they all map at the FAD binding site, which is
one of the crucial redox and catalytic cofactors of the protein (Fig. 4C).
Indeed, two of the ETF:QO mutations (Gl65E, A68V) are directly located
within the Rossmann fold, a nucleotide binding domain that begins
with a β-strand connected by a short loop to an α‐helix. For proteins
that bind nucleotide cofactors, such as FAD, this fold comprises the
expanded sequence motif V/IxGx1–2GxxGxxxG/A. This sequence allows
to: stabilise the β-strand and the α-helix, accommodate glycyl residues
located in the connecting loop of cofactor pocket, and stabilise interac-
tions between the two elements of secondary structure [14]. Therefore,
this region is particularly sensitive to amino acid changes as the speciﬁc
BA
C
Fig. 4.Mutations map within the FAD binding residues and Rossmann fold. Panel A: Two of the identiﬁed mutations in ﬂy ETF:QO alleles (marked with asterisk, top alignment) map
at the Rossmann fold (G65E and A68V), more speciﬁcally at FAD interacting positions (marked with dots in the alignment) and are found at the connecting loop between the beta
sheet and the alpha helix. The other mutation (S104F) also involves a position interacting with FAD at the level of the ﬂavin C2 carbon. Panel B: ETF:QO cartoon depicting the
different structural domains in the protein. Panel C: Structural detail of ETF:QO on which the identiﬁed mutations have been represented and a topological cartoon depicting
the Rossmann fold and FAD. See Results and discussion for further details.
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Rossmann fold itself.
Two of the three ETF:QODrosophilamutations are precisely located
in this connecting loop (Fig. S4). One of them affects position 65 in
which a glycine is replaced by the negatively charged glutamate
(G65E); this change is very deleterious for the protein as the inserted
residue causes an electrostatic clash with the negative charges from
the proximal pyrophosphate group from the FAD cofactor (Fig. S4D).
Moreover, the corresponding residue in the experimentally determined
ETF:QO porcine structure is an alanine, whose side chain methyl group
is indeed buried in a hydrophobic pocket (Fig. S4A). Therefore, the
replacement for a large hydrophilic residue, such as the one from the
glutamate, is indeed expected to be detrimental (Fig S4D). The other
mutation in the segment involves position 68, and in this case an
alanine is replaced by a valine (A68V); themutated alanine is hydrogen
bonded to the FAD pyrophosphate group through themain chain amide
nitrogen atom (Fig. S4B). Therefore the bulkier apolar side chain from a
valine will perturb the protein fold at the FAD binding site, which is
certainly resulting in an impaired interaction with the cofactor
(Fig. S4E). Interestingly, a mutation in the same relative position has
been found in one of the C. elegans ETF:QOmutant alleles. In the nema-
tode, this position in the primary sequence of ETF:QO corresponds to a
serine, a conservative change in respect to the alanine found in the
human and Drosophila proteins (see Fig. 4A). The change to a phenylal-
anine reported in the allele s2447 of let-721 results in maternal effect
lethality [16]. This ﬁnding corroborates the view that this is indeed a
hotspot segment region as mutations in these two speciﬁc positions
within the nucleotide bindingmotif of the Rossmann fold are anticipat-
ed to clearly affect FAD binding. The remaining mutation is found fur-
ther in the sequence at position 104, no longer within the Rossmann
fold, but still in a sequence stretch that harbours several residues that
interact with the isoallozaxine ring system of the FAD cofactor (Fig.
S4C and F). The affected residue in this case is a serinewhich is replaced
by the bulkier aromatic phenylalanine (S104F). This particular serine isa key residue in FAD interaction as its side chain hydroxyl group is
hydrogen bonded to that of the FAD C2 carbon (Fig. S4C). Therefore,
the insertion of a phenylalanine and its large aromatic ring severely
displaces this interaction, disrupting FAD binding and consequently
protein folding (Fig. S4F). In fact, a mutation in this position in human
ETF:QO completely abolishes soluble protein, thus conﬁrming the key
role of cofactors in the stability of the protein (Frank Frerman, personal
communication). Overall, the structural analysis of the mutations iden-
tiﬁed in the ETF:QOmutant alleles provides amolecular rationale for the
observed lethal phenotypes and anomalous metabolic proﬁle, as they
severely inﬂuence the FAD interaction affecting the protein structural
integrity and biological function.
3.7. Drosophila as a potential working model for MADD
Fatty acid oxidation (FAO) is a key cellular process in mitochondrial
metabolism as it affords a high supply of energy in tissues with elevated
metabolic rates such as heart and skeletal muscles [37]. Impaired fatty
acid oxidation as inMADD leads to the accumulation ofmetabolic inter-
mediates, down regulation of oxidative phosphorylation and Warburg
switching for energy production. The magnitude of mitochondrial
dysfunction relates to the severity of the functional impairment of the
pathway, which in turn relates to the affected gene and severity of the
genetic lesion. Model organisms have proven to be valuable tools to
address defectiveβ-oxidation disorders [38–41], andMADD in particular
[15,16]. To our knowledge other detailed available studies on Drosophila
FAO proteins focus on colt, a gene implicated in early embryonic devel-
opment which encodes for a carnitine acylcarnitine carrier (CACT) [42],
and Enigma, a gene encoding for a homologue of the acyl-CoA dehydro-
genase 9 (ACAD9) which upon mutation results in perturbed lipid
homeostasis, resistance to oxidative stress and a longevity phenotype
[43]. In humans, ACAD9 has a long-chain acyl-CoA dehydrogenase
activity in embryos and in the foetal brain [44]. Some other studies also
suggest that FAO is a key pathway in Drosophila, intertwined with
1291E. Alves et al. / Biochimica et Biophysica Acta 1822 (2012) 1284–1292other processes: for example ETF:QO is up-regulated as a response to a
24 hour starvation [45] and as a result of mitochondrial dysfunction
resulting from conditions mimicking mitochondrial disease [46].
Mining of the Drosophila genome shows the presence of homologues
of themammalian proteins involved in fatty acid oxidation and transport
whose transcriptome analysis denotes important expression levels of
these proteins at early stages of development (Table S2 and Fig. S1),
suggesting that this organism could be useful to study FAO defects.
Drosophila can in fact be envisaged as a potential working model
for MADD, as shown by the work here reported, as the three mutant
alleles identiﬁed in the ETF:QO gene result in low protein levels and
a lethal phenotype, as a result of point mutations at the ETF:QO FAD
binding region. If identical mutations would be found in humans
they would account for a severe form of the disease, with probable
embryonic death (MADD type II). In such circumstances, the underlying
molecular defects are not analysed as in such instances there is rarely
evidence for a defect in β-oxidation, unless in the cases of neonatal
death for which the so-called metabolic autopsy is carried out post-
mortem [20,37,47,48].4. Conclusions
Herewe have addressed lethal mutations in ETF:QOwhich reproduce
the biochemical defects observed in the severe forms of MADD in
humans, thus establishing the proof of principle concerning the suitability
of using Drosophila as a model for MADD. The studied alleles allowed
correlating embryonic-stage morphogenetic and biochemical defects
with a particular type of structural defect within the FAD binding region
of the Rossmann fold that impaired ﬂavin binding and correct protein
folding. This type of analysis using model organisms is extremely power-
ful, for example by providing a testable platform to identify what would
be the in vivo effects ofmutations identiﬁed in less severe formsof thedis-
ease, in respect to affected pathways or mitochondrial dysfunction. For
the mutations yielding mild clinical phenotypes, a ﬂy model would pro-
vide the unique opportunity for studying how MADD affects the
different stages of development, from the embryo stages to the adult
ﬂy. This systemwouldnot only contribute to a substantially better knowl-
edge of the molecular processes' affect in MADD but would also, in the
long run, contribute for the design and testing of potential drugs, from
pharmacological chaperones [49] to metabolites or their analogues [5].Acknowledgements
Frank Frerman (University of Colorado Denver, USA) is gratefully
acknowledged for discussion of results and for communicating
unpublished data. Rikke Olsen (Aarhus University, Denmark) is
acknowledged for the kind gift of a ETF:QO antibody. AdrianoHenriques
and Mónica Serrano (ITQB) are greatly acknowledged for advice on
molecular biology methods. This work was partly supported by the
Fundação para a Ciência e Tecnologia (FCT/MCTES, Portugal) through:
research grant PTDC/SAU-GMG/70033/2006 (to C.M.G), PTDC/QUI-
BIQ/113027/2009, PTDC/BIA-BCM/111822/2009, and PTDC/SAU-BID/
111796/2009 (to R.G.M.), fellowships SFRH/BPD/41609/2007 (to E.A.),
SFRH/BPD/74475/2010 (to B.J.H.) and SFRH/BPD/34763/2007 (to
J.V.R), and by the strategic grant PEst-OE/EQB/LA0004/2011 (to ITQB
Laboratório Associado). This work was also partly supported by a
CLIMB UK ‘Children living with metabolic disease’ research grant (to
C.M.G.).Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.05.003.References
[1] Z. Swigonova, A.W. Mohsen, J. Vockley, Acyl-CoA dehydrogenases: dynamic his-
tory of protein family evolution, J. Mol. Evol. 69 (2009) 176–193.
[2] B.J. Henriques, R.K. Olsen, P. Bross, C.M. Gomes, Emerging roles for riboﬂavin in
functional rescue of mitochondrial beta-oxidation ﬂavoenzymes, Curr. Med.
Chem. 17 (2010) 3842–3854.
[3] B.J. Henriques, P. Bross, C.M. Gomes, Mutational hotspots in electron transfer ﬂa-
voprotein underlie defective folding and function in multiple acyl-CoA dehydro-
genase deﬁciency, Biochim. Biophys. Acta 1802 (2010) 1070–1077.
[4] B.J. Henriques, J.V. Rodrigues, R.K. Olsen, P. Bross, C.M. Gomes, Role of
ﬂavinylation in a mild variant of multiple acyl-CoA dehydrogenation deﬁciency:
a molecular rationale for the effects of riboﬂavin supplementation, J. Biol. Chem.
284 (2009) 4222–4229.
[5] T.G. Lucas, B.J. Henriques, J.V. Rodrigues, P. Bross, N. Gregersen, C.M. Gomes, Co-
factors and metabolites as potential stabilizers of mitochondrial acyl-CoA dehy-
drogenases, Biochim. Biophys. Acta 1812 (2011) 1658–1663.
[6] T.M. Dwyer, S. Mortl, K. Kemter, A. Bacher, A. Fauq, F.E. Frerman, The intraﬂavin
hydrogen bond in human electron transfer ﬂavoprotein modulates redox poten-
tials and may participate in electron transfer, Biochemistry 38 (1999) 9735–9745.
[7] J.V. Rodrigues, C.M. Gomes, Mechanism of Superoxide and Hydrogen Peroxide
Generation by Human Electron Transfer Flavoprotein and Pathological Variants,
Free Radical Biology and Medicine (2012).
[8] D.L. Roberts, F.E. Frerman, J.J. Kim, Three-dimensional structure of human elec-
tron transfer ﬂavoprotein to 2.1-A resolution, Proc. Natl. Acad. Sci. U. S. A. 93
(1996) 14355–14360.
[9] J. Zhang, F.E. Frerman, J.J. Kim, Structure of electron transfer ﬂavoprotein–ubiqui-
none oxidoreductase and electron transfer to the mitochondrial ubiquinone pool,
Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 16212–16217.
[10] R.P. McAndrew, Y. Wang, A.W. Mohsen, M. He, J. Vockley, J.J. Kim, Structural basis
for substrate fatty acyl chain speciﬁcity: crystal structure of human very-long-
chain acyl-CoA dehydrogenase, J. Biol. Chem. 283 (2008) 9435–9443.
[11] H.J. Lee, M. Wang, R. Paschke, A. Nandy, S. Ghisla, J.J. Kim, Crystal structures of the
wild type and the Glu376Gly/Thr255Glu mutant of human medium-chain acyl-
CoA dehydrogenase: inﬂuence of the location of the catalytic base on substrate
speciﬁcity, Biochemistry 35 (1996) 12412–12420.
[12] J.J. Kim, M. Wang, R. Paschke, Crystal structures of medium-chain acyl-CoA dehy-
drogenase from pig liver mitochondria with and without substrate, Proc. Natl.
Acad. Sci. U. S. A. 90 (1993) 7523–7527.
[13] K.P. Battaile, J. Molin-Case, R. Paschke, M. Wang, D. Bennett, J. Vockley, J.J. Kim,
Crystal structure of rat short chain acyl-CoA dehydrogenase complexed with
acetoacetyl-CoA: comparison with other acyl-CoA dehydrogenases, J. Biol.
Chem. 277 (2002) 12200–12207.
[14] G. Kleiger, D. Eisenberg, GXXXG and GXXXA motifs stabilize FAD and NAD(P)-
binding Rossmann folds through C(alpha)–H. O hydrogen bonds and van der
waals interactions, J. Mol. Biol. 323 (2002) 69–76.
[15] Y. Song, M.A. Selak, C.T. Watson, C. Coutts, P.C. Scherer, J.A. Panzer, S. Gibbs, M.O.
Scott, G. Willer, R.G. Gregg, D.W. Ali, M.J. Bennett, R.J. Balice-Gordon, Mechanisms
underlying metabolic and neural defects in zebraﬁsh and human multiple acyl-
CoA dehydrogenase deﬁciency (MADD), PLoS One 4 (2009) e8329.
[16] D.S. Chew, A.K. Mah, D.L. Baillie, Characterizing the transcriptional regulation of
let-721, a Caenorhabditis elegans homolog of human electron ﬂavoprotein dehy-
drogenase, Mol. Genet. Genomics 282 (2009) 555–570.
[17] A. Pimenta-Marques, R. Tostoes, T. Marty, V. Barbosa, R. Lehmann, R.G. Martinho,
Differential requirements of a mitotic acetyltransferase in somatic and germ line
cells, Dev. Biol. 323 (2008) 197–206.
[18] T.B. Chou, N. Perrimon, Use of a yeast site-speciﬁc recombinase to produce female
germline chimeras in Drosophila, Genetics 131 (1992) 643–653.
[19] L.G. Guilgur, P. Prudencio, T. Ferreira, A.R. Pimenta-Marques, R.G. Martinho, Dro-
sophila aPKC is required for mitotic spindle orientation during symmetric divi-
sion of epithelial cells, Development 139 (2012) 503–513.
[20] M.S. Rashed, P.T. Ozand, M.P. Bucknall, D. Little, Diagnosis of inborn errors of me-
tabolism from blood spots by acylcarnitines and amino acids proﬁling using auto-
mated electrospray tandem mass spectrometry, Pediatr. Res. 38 (1995) 324–331.
[21] C. Watters, A one-step Biuret assay for protein in the presence of detergent, Anal.
Biochem. 88 (1978) 695–698.
[22] C. Welinder, L. Ekblad, Coomassie staining as loading control in Western blot
analysis, J. Proteome Res. 10 (2011) 1416–1419.
[23] R.K. Olsen, B.S. Andresen, E. Christensen, P. Bross, F. Skovby, N. Gregersen, Clear
relationship between ETF/ETFDH genotype and phenotype in patients with mul-
tiple acyl-CoA dehydrogenation deﬁciency, Hum. Mutat. 22 (2003) 12–23.
[24] J.D. Beckmann, F.E. Frerman, Electron-transfer ﬂavoprotein–ubiquinone oxidore-
ductase from pig liver: puriﬁcation andmolecular, redox, and catalytic properties,
Biochemistry 24 (1985) 3913–3921.
[25] J.D. Beckmann, F.E. Frerman, Reaction of electron-transfer ﬂavoprotein with
electron-transfer ﬂavoprotein–ubiquinone oxidoreductase, Biochemistry 24
(1985) 3922–3925.
[26] K.B. Nicholas, H.B. Nicholas, D.W. Deerﬁeld, GeneDoc: analysis and visualization
of genetic variation, EMBNEW NEWS 4 (1) (1997) 1–4.
[27] G. Vriend, WHAT IF: a molecular modeling and drug design program, J. Mol.
Graph. 8 (1990) 52–56 (29).
[28] M.C. McKean, J.D. Beckmann, F.E. Frerman, Subunit structure of electron transfer
ﬂavoprotein, J. Biol. Chem. 258 (1983) 1866–1870.
[29] W. Rhead, V. Roettger, T. Marshall, B. Amendt, Multiple acyl-coenzyme A dehy-
drogenation disorder responsive to riboﬂavin: substrate oxidation, ﬂavin metab-
olism, and ﬂavoenzyme activities in ﬁbroblasts, Pediatr. Res. 33 (1993) 129–135.
1292 E. Alves et al. / Biochimica et Biophysica Acta 1822 (2012) 1284–1292[30] F.W. Studier, Protein production by auto-induction in high density shaking cul-
tures, Protein Expr. Purif. 41 (2005) 207–234.
[31] X. Liu, I. Kiss, J.A. Lengyel, Identiﬁcation of genes controlling malpighian tubule
and other epithelial morphogenesis in Drosophila melanogaster, Genetics 151
(1999) 685–695.
[32] W. Lehnert, U. Wendel, S. Lindenmaier, N. Bohm, Multiple acyl-CoA dehydrogena-
tion deﬁciency (glutaric aciduria type II), congenital polycystic kidneys, and sym-
metric warty dysplasia of the cerebral cortex in two brothers. I. Clinical,
metabolical, and biochemical ﬁndings, Eur. J. Pediatr. 139 (1982) 56–59.
[33] F.E. Frerman, S.I. Goodman, Deﬁciency of electron transfer ﬂavoprotein or elec-
tron transfer ﬂavoprotein:ubiquinone oxidoreductase in glutaric acidemia type
II ﬁbroblasts, Proc. Natl. Acad. Sci. U. S. A. 82 (1985) 4517–4520.
[34] A.D. Colevas, J.L. Edwards, R.H. Hruban, G.A. Mitchell, D. Valle, G.M. Hutchins,
Glutaric acidemia type II. Comparison of pathologic features in two infants,
Arch. Pathol. Lab. Med. 112 (1988) 1133–1139.
[35] G.N. Wilson, J.P. de Chadarevian, P. Kaplan, J.P. Loehr, F.E. Frerman, S.I. Goodman,
Glutaric aciduria type II: review of the phenotype and report of an unusual
glomerulopathy, Am. J. Med. Genet. 32 (1989) 395–401.
[36] M. Simkovic, G.D. Degala, S.S. Eaton, F.E. Frerman, Expression of human electron
transfer ﬂavoprotein–ubiquinone oxidoreductase from a baculovirus vector: kinetic
and spectral characterization of the humanprotein, Biochem. J. 364 (2002) 659–667.
[37] M.J. Bennett, P. Rinaldo, A.W. Strauss, Inborn errors of mitochondrial fatty acid
oxidation, Crit. Rev. Clin. Lab. Sci. 37 (2000) 1–44.
[38] R.J. Tolwani, D.A. Hamm, L. Tian, J.D. Sharer, J. Vockley, P. Rinaldo, D. Matern, T.R.
Schoeb, P.A. Wood, Medium-chain acyl-CoA dehydrogenase deﬁciency in gene-
targeted mice, PLoS Genet. 1 (2005) e23.
[39] H. Skilling, P.M. Coen, L. Fairfull, R.E. Ferrell, B.H. Goodpaster, J. Vockley, E.S.
Goetzman, Brown adipose tissue function in short-chain acyl-CoA dehydrogenase
deﬁcient mice, Biochem. Biophys. Res. Commun. 400 (2010) 318–322.
[40] A.A. Werdich, F. Baudenbacher, I. Dzhura, L.H. Jeyakumar, P.J. Kannankeril, S.
Fleischer, A. LeGrone, D. Milatovic, M. Aschner, A.W. Strauss, M.E. Anderson, V.J.
Exil, Polymorphic ventricular tachycardia and abnormal Ca2+ handling in very-long-chain acyl-CoA dehydrogenase null mice, Am. J. Physiol. Heart Circ. Physiol.
292 (2007) H2202–H2211.
[41] M. Chegary, H. Brinke, J.P. Ruiter, F.A. Wijburg, M.S. Stoll, P.E. Minkler, M. van
Weeghel, H. Schulz, C.L. Hoppel, R.J. Wanders, S.M. Houten, Mitochondrial long
chain fatty acid beta-oxidation in man and mouse, Biochim. Biophys. Acta 1791
(2009) 806–815.
[42] N.A. Oey, L. Ijlst, C.W. van Roermund, F.A. Wijburg, R.J. Wanders, dif-1 and colt,
both implicated in early embryonic development, encode carnitine acylcarnitine
translocase, Mol. Genet. Metab. 85 (2005) 121–124.
[43] P. Mourikis, G.D. Hurlbut, S. Artavanis-Tsakonas, Enigma, a mitochondrial protein
affecting lifespan and oxidative stress response in Drosophila, Proc. Natl. Acad. Sci.
U. S. A. 103 (2006) 1307–1312.
[44] N.A. Oey, J.P. Ruiter, T. Attie-Bitach, L. Ijlst, R.J. Wanders, F.A. Wijburg, Fatty acid
oxidation in the human fetus: implications for fetal and adult disease, J. Inherit.
Metab. Dis. 29 (2006) 71–75.
[45] K. Fujikawa, A. Takahashi, A. Nishimura, M. Itoh, T. Takano-Shimizu, M. Ozaki,
Characteristics of genes up-regulated and down-regulated after 24 h starvation
in the head of Drosophila, Gene 446 (2009) 11–17.
[46] D.J. Fernandez-Ayala, S. Chen, E. Kemppainen, K.M. O'Dell, H.T. Jacobs, Gene ex-
pression in a Drosophila model of mitochondrial disease, PLoS One 5 (2010)
e8549.
[47] M.S. Rashed, P.T. Ozand, M.J. Bennett, J.J. Barnard, D.R. Govindaraju, P. Rinaldo, In-
born errors of metabolism diagnosed in sudden death cases by acylcarnitine anal-
ysis of postmortem bile, Clin. Chem. 41 (1995) 1109–1114.
[48] T. Yamamoto, H. Tanaka, H. Kobayashi, K. Okamura, T. Tanaka, Y. Emoto, K.
Sugimoto, M. Nakatome, N. Sakai, H. Kuroki, S. Yamaguchi, R. Matoba, Retrospec-
tive review of Japanese sudden unexpected death in infancy: the importance of
metabolic autopsy and expanded newborn screening, Mol. Genet. Metab. 102
(2011) 399–406.
[49] P. Leandro, C.M. Gomes, Protein misfolding in conformational disorders: rescue of
folding defects and chemical chaperoning, Mini Rev. Med. Chem. 8 (2008)
901–911.
